Kenneth Galbraith, Zymeworks CEO
December 19, 2022 11:35 AM EST
R&D

Zymeworks shows pos­i­tive — yet ear­ly — piv­otal da­ta in bile duct can­cers, plans ac­cel­er­at­ed ap­proval run

Paul Schloesser

Associate Editor

Zymeworks is show­ing off some new topline da­ta on its HER2 bis­pe­cif­ic an­ti­body — af­ter show­cas­ing a pos­i­tive da­ta turnout at AS­CO ear­li­er in 2022. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times